News | PET Imaging | August 24, 2018

Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Military personnel show brain changes similar to those seen in retired football players with suspected CTE on PET scans

Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

August 24, 2018 — In a small study of military personnel who had suffered head trauma and had reported memory and mood problems, researchers found brain changes similar to those seen in retired football players with suspected chronic traumatic encephalopathy (CTE).

CTE occurs in people who have had multiple head injuries. Recent studies and headlines have focused on former football players who exhibited symptoms such as depression, confusion and mood swings. In later stages, CTE can lead to symptoms of Alzheimer's disease and other forms of dementia. Currently, CTE can only be diagnosed after death, when examination of brain tissue reveals clumps of a protein called tau, which kills brain cells.

To aid in diagnosing CTE in living individuals, researchers at the University of California Los Angeles (UCLA) are studying a molecular tracer, called FDDNP, which binds with tau as well as another abnormal protein called amyloid. The tracer, given intravenously, shows up in positron emission tomography (PET) brain scans, pointing to the location and extent of abnormal proteins in the brain.

Previously, UCLA researchers used the tracer to study the brains of 15 former National Football League (NFL) players with memory and mood problems. In that study, the pattern of abnormal protein distribution in living patients was consistent with the tau distribution seen in autopsy-confirmed CTE cases.

For the current study, which builds upon the earlier research, seven military personnel (five veterans and two in active duty) who had suffered mild traumatic brain injuries and had memory or mood complaints underwent neuropsychiatric evaluations. They had brain scans after being injected with FDDNP, the molecular tracer. The results were compared to those of the 15 previously studied football players, as well as 24 people with Alzheimer's dementia and 28 people without cognitive problems, for comparison.

The location and quantity of the tracer in the brains of the military personnel were similar to that seen in retired football players and distinct from the distribution patterns seen in people with Alzheimer's disease or in healthy individuals.

Larger studies using FDDNP and brain scans in people at risk for chronic traumatic encephalopathy are needed to confirm the usefulness of FDDNP as a diagnostic tool. The ability to diagnose CTE in living individuals would help scientists observe the progression of the disease, develop treatments and quantify the scope of CTE among different populations, such as military veterans.

Gary Small, M.D., a professor of psychiatry and biobehavioral sciences at UCLA and director of the Longevity Center at UCLA's Semel Institute for Neuroscience and Human Behavior, is the study's senior author. The study appears in the July 17 Journal of Alzheimer's Disease.

For more information: www.j-alz.com

Reference

Small G.W., Chen S., Siddarth P., et al. FDDNP-PET Tau Brain Protein Binding Patterns in Military Personnel with Suspected Chronic Traumatic Encephalopathy. Journal of Alzheimer’s Disease, Aug. 7, 2018. DOI: 10.3233/JAD-171152

Related Content

MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more
SBRT Considered Safe Treatment Option for Patients With Multiple Metastases
News | Stereotactic Body Radiation Therapy (SBRT) | November 01, 2018
The NRG Oncology clinical trial BR001 tested the hypothesis that stereotactic body radiotherapy (SBRT) could be used...